A risk prediction system of postoperative hemorrhage following laparoscopy-assisted radical gastrectomy with D2 lymphadenectomy for primary gastric cancer

Xin-Sheng Xie1,2,3,4,*, Jian-Xian Lin1,2,3,4,*, Ping Li1,2,3,4, Jian-Wei Xie1,2, Jia-Bin Wang1,2,3,4, Jun Lu1,2, Qi-Yue Chen1,2, Long-Long Cao1,2, Mi Lin1,2, Ru-Hong Tu1,2, Chang-Ming Huang1,2,3,4 and Chao-Hui Zheng1,2

1Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China
2Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China
3Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian Province, China
4Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, Fujian Province, China

*These authors contributed equally to this work and share co-first authorship

Correspondence to: Chang-Ming Huang, email: hcmlr2002@163.com
Chao-Hui Zheng, email: wwkzch@163.com

Keywords: gastric cancer, postoperative hemorrhage, laparoscopy, D2 lymphadenectomy, risk factor

Received: July 14, 2017 Accepted: August 27, 2017 Published: September 11, 2017

ABSTRACT

Objectives: To investigate risk factors of postoperative hemorrhage (PH) following laparoscopy-assisted radical gastrectomy (LARG) with D2 lymphadenectomy for primary gastric cancer (PGC) and to use those risk factors to develop a scoring system for risk assessment.

Materials and Methods: A total of 1789 PGC patients were enrolled in our study. We analyzed the risk factors of PH and constructed a scoring system using 75% of the cases as the experimental group and 25% of the cases as a verification group to demonstrate the effectiveness.

Results: Among these 1789 patients, 46 (2.6%) developed PH. Univariate and multivariate analysis in the experimental group indicated that having more than 41 lymph node excisions, combined organ resection, stage III tumor and postoperative digestive fistula were independent risk factors of PH. According to the independent risk factors, we constructed a scoring system to separate patients into low-risk (0–2 points) and high-risk (≥ 3 points) groups. The area under the ROC curve for this scoring system was 0.748. In the verification group, the risk of PH predicted by the scoring system was not significantly different from the actual incidence observed.

Conclusions: This scoring system could simply and effectively predict the occurrence of PH following LARG with D2 lymphadenectomy for PGC. The predictive system will help surgeons evaluate risk and select risk-adapted interventions to improve surgical safety.

INTRODUCTION

Although the morbidity and mortality of the primary gastric cancer has declined in recent decades, it is still the second most common cause of cancer-related death worldwide [1–3]. Surgery remains the most important intervention for primary gastric cancer (PGC), and radical gastrectomy with D2 lymphadenectomy has become the standard procedure [4, 5]. Even with recent developments in surgical technology, postoperative complications are still difficult to avoid. Compared with the postoperative anastomotic stenosis and gastric paralysis, postoperative
complications such as chylous fistula and postoperative hemorrhage (PH) often occur under emergency conditions and endanger the patient’s life [6, 7]. If we can identify the risk factors of PH following gastric cancer (GC), we could perform a risk assessment and determine appropriate perioperative interventions which would be helpful in reducing the mortality of PH following GC.

Research concerning the risk of PH following laparoscopy-assisted radical gastrectomy (LARG) is very limited. Therefore, this study analyzed the risk factors as they relate to the incidences of PH in 1789 patients who underwent LARG with D2 lymphadenectomy in our department. We also established a new, simple and practical scoring system to help surgeons assess and predict the risk of PH following gastrectomy.

MATERIALS AND METHODS

Materials

This study was a retrospective analysis of a prospectively collected database of 1789 PGC patients treated with LARG with D2 lymphadenectomy in the Department of Gastric Surgery of Fujian Medical University Union Hospital, Fuzhou, China, between May 2007 and September 2013. All the clinicopathologic data of patients were recorded in a clinical data system for gastric cancer surgery. The tumor stage was determined based on the 8th edition (2016) of the International Union against Cancer (UICC) tumor, lymph node and distant metastasis (TNM) classification [8, 9]. Patients with intraoperative evidence of peritoneal dissemination, invasion of the adjacent organs, suffer from coagulation disorders or a distant metastasis, conversion to an open laparotomy or incomplete pathological data were not included in this study. All patients voluntarily chose laparoscopic surgery, and signed an informed consent following an explanation of the surgical and oncological risks. The type of surgical resection and the extent of lymphadenectomy were selected according to the 4th edition Japan stomach cancer treatment guidelines [4]. {Association1, 2016 #1} All LARG procedures were carried out by the same group of surgeons.

Variables and definitions

The definition of PH, based on the literature, is blood flow out of the surgical site with a drop in hemoglobin of more than 2 g/dl in 24 hours usually accompanied by hemorrhage and requiring at least 2 units of packed red blood cells [10–12]. The diagnostic procedures of PH were considered as follow: clinical manifestation, blood routine, blood pressure measurement, bedside ultrasonography, abdominocentesis, or angiography and so on. We considered every 24 hours after surgery as one day and defined the day of diagnosis when patients showed the signs of bleeding or bleeding confirmed by auxiliary examinations. The potential risk factors for PH were extracted from the database. These included gender, age, body mass index (BMI), previous abdominal surgery, tumor location, tumor size, TNM stage, operative time (recorded from the skin incision to skin closure), type of surgical resection, type of reconstruction, blood loss during the operation, number of resected lymph nodes, combined organ resection, digestive tract fistula, pure abdominal infection and chylous fistula.

Statistical analysis

All statistical analyses were performed using the Statistical Package for Social Science (SPSS) version 23.0 for Windows (IBM, Chicago, IL, USA). The results were expressed as percentages or as the means ± standard deviation (SD) unless otherwise noted. Data were analyzed using the chi-squared test, Fisher’s exact test or student’s t-test. Risk factors for PH were assessed by univariate and multivariate analyses using a logistic regression model. The variables with \( P < 0.05 \) in the univariate analysis were subsequently transformed into appropriate binary classification variables and included in a multivariate binary logistic regression model. The data from the multivariate analysis and the grouping of each risk are shown as OR values with corresponding 95% confidence intervals. The receiver operating characteristic (ROC) curve was calculated to assess the reliability of this model to distinguish between patients with and without PH. The area under the curve (AUC) was also measured, shown as the absolute value and 95% confidence interval (95% CI). An area under the curve of 0.7 or above was considered clinically significant. To build a scoring system to predict risk, patients were assigned random numbers and sorted in numerical order. The 75% of patients with the largest numbers were assigned to the experimental group; the others were assigned to the validation group. The validated prediction system categorized patients as high-risk or low-risk according to their score. We verified the accuracy of the prediction system by comparing the difference between the incidence of prediction and the actual incidence of PH. \( P \) values \(< 0.05\) were considered statistically significant.

RESULTS

The occurrence of PH and the clinicopathological factors between the experimental and verification group

There were 1789 cases of patients who underwent LARG with D2 lymphadenectomy for primary gastric cancer. Among them, 46 (2.6%) suffered from PH. Of the 46, 37 (80.4%) were male and 9 (19.6%) were female; the mean age and BMI were 60.56 ± 11.14 years and
22.18 ± 2.96 kg/m², respectively. On average, hemorrhage usually occurred in the fifth day after surgery. The clinicopathological factors of the two groups are shown in Table 1.

Univariate analysis of PH in the experimental group

The univariate analysis of PH in the experimental group indicated that tumor stage (P < 0.001), number of lymph nodes excised (P < 0.05), combined organ resection (P < 0.001) and postoperative digestive tract fistula (P < 0.001) were related to PH, with the differences showing statistical significance. However, gender, age, BMI, previous abdominal surgery, tumor size, tumor location, operative time, blood loss during the operation, operation and anastomotic methods, pure abdominal infection and chylous fistula had no effect on PH (P > 0.05). See Table 2.

Multivariate analysis of PH in the experimental group

The multivariate logistic regression analysis revealed that stage III tumors (P = 0.005, OR = 3.654), more than 41 lymph node excisions (P = 0.046, OR = 2.094), combined organs resection (P = 0.018, OR = 2.779) and postoperative digestive tract fistula (P < 0.001, OR = 6.898) were the independent risk factors of PH after LARG with D2 lymphadenectomy for primary gastric cancer. See Table 3.

Risk gradation of PH and construction of the predictive scoring system

Because the differences in the regression coefficients ranged from 0.586 to 0.812, risk factors were simplified to the following weights based on their regression coefficients: a stage III tumor was denoted as 1 point, number of lymph node excisions ≥ 41 was denoted as 1 point, combined organ resection was denoted as 1 point and postoperative digestive tract fistula was denoted as 2 points. Based on these scores, patients were divided into low-risk (0 to 2 points) and high-risk (more than 3 points) groups. The low-risk group had 95.2% of the patients and the high-risk group had 4.8%. The hemorrhage rates were 2.0% and 13.8% in the low-risk and high-risk groups, respectively. Compared with the low-risk patients, the relative risk of high-risk patients was 8.04 (95% CI: 3.589–18.084, p<0.001). See Table 4.

The effectiveness test of the predictive scoring system

The receiver operating characteristic (ROC) curve of this scoring system was calculated, and the area under the curve (AUC) was 0.748; see Figure 1. Detailed patient conditions in each group are shown in Table 5, which uses the scoring system to score and risk-stratify the validation group. The effectiveness test of the predictive scoring system was verified by determining whether there were differences between the predicted hemorrhage rate and the actual bleeding rate. We compared differences between high-risk and low-risk patients in the validation group with the actual rate of PH and the predicted rate of hemorrhage. There was no significant difference between them; the p values were 0.400 and 0.881 for the low-risk group and high-risk group, respectively. This indicated that the scoring system could accurately predict PH. See Table 5.

DISCUSSION

Gastric cancer is one of the most common gastrointestinal malignancies. Its related disease mortality is second only to lung cancer [13–15]. To date, surgical resection is the primary intervention for GC [16]. With improvements in laparoscopic technology and surgical technique, laparoscopic surgery has become a common approach to surgical resection [14]. The number of applications for laparoscopic surgery has also increased. Although surgical treatment with R0 resection has become more common, postoperative complications remain a problem. Many centers reported that the incidence of the postoperative complications following LARG range from 11.6% to 18.7% [15, 16], and certain departments have reached incidence rates ranging from 24.9% to 42.6% [17, 18]. PH is one of the more serious complications. The literature reports that the incidence rate of PH following GC ranges from 0.6% to 3.3% and has a high mortality. [19, 20] In this study, the incidence rate of PH was 2.57%. Although we found a lower incidence of PH, it was still lethal. When patients present with PH, they tend to have longer hospital stays, more expensive treatments and a significantly increased risk of death [21]. Because of its severity, it is particularly important to effectively prevent PH following gastrectomy.

The risk factors for PH following gastrectomy are still controversial. Song et al. [21] believed that extensive lymph node excision and later tumor stages were the independent risk factors of PH. Park et al. [22] retrospectively analyzed clinical data from 5739 patients who suffered from PH following gastrectomy to treat PGC. Their results showed that 42% of patients with a PH complication had an early abdominal infection; another 62% had anastomotic or pancreatic leakage. They also reported that male gender and previous abdominal surgery were associated with PH following gastrectomy and have no relationship with neoadjuvant chemotherapy. Jeong et al. [23] reported that a higher BMI is associated with PH following gastrectomy. The present study shows that patients with at least 41 lymph nodes excised, a later tumor TNM stage (stage...
Table 1: The clinicopathological factors between the experimental group and the verification group

| Variables                  | Experimental group (n = 1342) | Verification group (n = 447) |
|----------------------------|-------------------------------|-----------------------------|
|                            | Hemorrhage (n = 34) | No hemorrhage (n = 1308) | Hemorrhage (n = 12) | No hemorrhage (n = 435) |
| Gender                     | ±                            |                             |                             |                             |
| Male                       | 27                           | 998                         | 10                         | 308                        |
| Female                     | 7                            | 310                         | 2                          | 127                        |
| Age (years)                | 63.06 ± 12.79                | 60.43 ± 11.13               | 62.08 ± 16.08              | 60.73 ± 10.88              |
| BMI (kg/m²)                | 21.47 ± 2.18                 | 22.19 ± 3.01                | 22.1 ± 2.22                | 22.2 ± 2.88                |
| PAS                        |                               |                             |                             |                             |
| Yes                        | 6                            | 176                         | 1                          | 68                         |
| No                         | 28                           | 1132                        | 11                         | 367                        |
| Tumor size (cm)            | 48.78 ± 19.29                | 46.27 ± 25.27               | 52.08 ± 25.54              | 46.84 ± 25.77              |
| Tumor location             |                               |                             |                             |                             |
| Upper                      | 13                           | 304                         | 6                          | 117                        |
| Middle                     | 2                            | 210                         | 1                          | 64                         |
| Lower                      | 14                           | 656                         | 3                          | 206                        |
| Diffuse                    | 5                            | 138                         | 2                          | 48                         |
| TNM stage                  |                               |                             |                             |                             |
| I/II                       | 28                           | 681                         | 7                          | 217                        |
| III                        | 6                            | 627                         | 5                          | 218                        |
| Operation time (min)       | 199.65 ± 62.75               | 190.19 ± 61.72              | 240.00 ± 94.89             | 196.48 ± 67.45             |
| BLDO (ml)                  | 118.24 ± 143.43              | 85.73 ± 103.39              | 100.50 ± 80.52             | 84.83 ± 86.88              |
| Resected LNs (n)           | 32.13 ± 10.27                | 33.91 ± 13.15               | 31.83 ± 7.03               | 34.71 ± 13.90              |
| Operation type             |                               |                             |                             |                             |
| Total                      | 19                           | 623                         | 9                          | 227                        |
| Subtotal                   | 15                           | 685                         | 3                          | 208                        |
| Type of Anastomosis        |                               |                             |                             |                             |
| Roux-en-Y                  | 19                           | 622                         | 1                          | 11                         |
| B-I                        | 9                            | 538                         | 2                          | 156                        |
| B-II                       | 5                            | 120                         | 0                          | 41                         |
| Esophagogastric            | 1                            | 28                          | 9                          | 227                        |
| Combined resection         |                               |                             |                             |                             |
| Yes                        | 9                            | 98                          | 5                          | 32                         |
| No                         | 25                           | 1210                        | 7                          | 403                        |
| DTF                        |                               |                             |                             |                             |
| Yes                        | 6                            | 36                          | 3                          | 5                          |
| No                         | 28                           | 1272                        | 9                          | 430                        |
| PAI                        |                               |                             |                             |                             |
| Yes                        | 3                            | 39                          | 0                          | 12                         |
| No                         | 31                           | 1269                        | 12                         | 423                        |
| Chylous fistula            |                               |                             |                             |                             |
| Yes                        | 3                            | 42                          | 1                          | 15                         |
| No                         | 31                           | 1266                        | 11                         | 420                        |
| Hospital stay (days)       | 20.09 ± 9.67                 | 13.86 ± 7.64                | 19.92 ± 7.28               | 14.36 ± 9.29               |

PAS: Previous abdominal surgery; PAI: Pure abdominal infection; DTF: Digestive tract fistula; BLDO: blood loss during the operation.
| Variables                      | Early Hemorrhage ($n = 34$) | Later Hemorrhage ($n = 34$) | No Hemorrhage ($n = 1308$) | $P$ value |
|-------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------|
| Gender                        |                             |                             |                             | 0.673     |
| Male                          | 27                          |                             | 998                         |           |
| Female                        | 7                           |                             | 310                         |           |
| Age(years)                    |                             |                             |                             | 0.192     |
| $\leq 65$                     | 16                          |                             | 473                         |           |
| $< 65$                        | 18                          |                             | 835                         |           |
| BMI (kg/m$^2$)                |                             |                             |                             | 0.093     |
| $\geq 25$                     | 3                           |                             | 269                         |           |
| $< 25$                        | 31                          |                             | 1039                        |           |
| PAS                           |                             |                             |                             | 0.481     |
| Yes                           | 6                           |                             | 176                         |           |
| No                            | 28                          |                             | 1132                        |           |
| Tumor size (cm)               |                             |                             |                             | 0.266     |
| $\geq 46$                     | 19                          |                             | 605                         |           |
| $< 46$                        | 15                          |                             | 703                         |           |
| Tumor location                |                             |                             |                             | 0.094     |
| Upper                        | 13                          |                             | 304                         |           |
| Middle                        | 2                           |                             | 210                         |           |
| Lower                        | 14                          |                             | 656                         |           |
| Diffuse                      | 5                           |                             | 138                         |           |
| TNM stage                     |                             |                             |                             | 0.000     |
| I/ II                         | 6                           |                             | 627                         |           |
| III                           | 28                          |                             | 681                         |           |
| Operation time (min)          |                             |                             |                             | 0.475     |
| $\geq 190$                    | 14                          |                             | 461                         |           |
| $< 190$                      | 20                          |                             | 847                         |           |
| BLDO (ml)                     |                             |                             |                             | 0.366     |
| $\geq 100$                    | 22                          |                             | 939                         |           |
| $< 100$                      | 12                          |                             | 369                         |           |
| Resected LNs ($n$)            |                             |                             |                             | 0.001     |
| $\geq 41$                    | 16                          |                             | 306                         |           |
| $< 41$                      | 18                          |                             | 1002                        |           |
| Operation type                |                             |                             |                             | 0.342     |
| Total                         | 15                          |                             | 685                         |           |
| Subtotal                      | 19                          |                             | 623                         |           |
| Type of Anastomosis           |                             |                             |                             | 0.332     |
| Anastomosis Anastomosis       |                             |                             |                             |           |
| Roux-en-Y                     | 19                          |                             | 622                         |           |
| B-I                           | 9                           |                             | 538                         |           |
| B-II                          | 5                           |                             | 120                         |           |
| Esophagogastric               | 1                           |                             | 28                          |           |
| Combined resection            |                             |                             |                             | 0.000     |
| Yes                           | 9                           |                             | 98                          |           |
| No                            | 25                          |                             | 1210                        |           |
III tumor), intraoperative combined organ resection and postoperative digestive tract leakage have a significantly higher risk of PH. Lymph nodes are located throughout the body near arteries and their branches. To achieve a radical cure, the surgeon must remove metastatic tissue from lymph nodes. This process requires stripping the lymph nodes and clearing nearby blood vessels. During lymphadenectomy, the high temperature of the ultrasonic knife may injure blood vessel walls and adjacent tissue, facilitating vascular damage and aneurysm formation.

|                      | Yes | No |
|----------------------|-----|----|
| DTF                  | 6   | 28 |
| PAI                  | 3   | 31 |
| Chylous fistula      | 3   | 31 |

| Hospital stay (days) | 20.09 ± 9.67 | 13.86 ± 7.64 |

PAS: Previous abdominal surgery; PAI: Pure abdominal infection; DTF: Digestive tract fistula; BLDO: blood loss during the operation.

Figure 1: Receiver operating characteristic (ROC) curves for the logistic regression model and predictive scoring system for bleeding risk after LARG with D2 lymphadenectomy for PGC; the area under the ROC curve was 0.758 (0.674–0.842) for the logistic regression model, and 0.748 (0.663–0.834) for the simplified score system.
which can result in PH. In addition, combined organ resection usually expands the scope of the operation and makes wounds larger and PH more likely to occur. Our data also show that patients who suffered from postoperative gastrointestinal leakage have a high likelihood of PH occurring. The risk of PH in these patients is as much as 6.898 times greater than the risk of PH in patients without gastrointestinal leakage (95% CI: 2.551–18.653, P < 0.001). The body is stressed and has local inflammation after gastrectomy. Moreover, when patients suffer from postoperative gastrointestinal leakage, digestive juices seep into the abdominal cavity or the wound and erode blood vessels, resulting in arterial rupture or aneurysm formation. According to Japan's 14th edition of the gastric cancer treatment statute, [4], patients diagnosed with PGC at an advanced stage often need to expand scope during LARG with D2 lymphadenectomy. Surgeons will also resect other organs for the R0 resection when necessary. Therefore, patients with a later tumor TNM stage were usually in the high-risk group for PH. Once postoperative gastrointestinal leakage is found, surgeons should prepare for the possibility of subsequent hemorrhage and take strict precautions and appropriate perioperative interventions to reduce the risk of bleeding.

Although our study shows that PH following LARG with D2 lymphadenectomy for PGC was closely related

### Table 3: Multivariate analysis of PH

| Variables                  | χ²   | B    | OR       | 95% CI               | P value | Score |
|----------------------------|------|------|----------|----------------------|---------|-------|
| TNM stage III              | 7.894| 1.296| 3.654    | 1.480–9.025          | 0.005   | 1     |
| Resected LNs (n) ≥ 41      | 3.993| 0.739| 2.094    | 1.014–4.322          | 0.046   | 1     |
| Combined resection Yes     | 5.630| 1.022| 2.779    | 1.195–6.463          | 0.018   | 1     |
| DTF Yes                    | 14.478| 1.931| 6.898    | 2.551–18.653         | 0.000   | 2     |

DTF: Digestive tract fistula.

### Table 4: Risk gradation of PH

| Risk gradation | Risk factor | Case number (n, %) | Hemorrhage rate (n, %) | OR       | 95% CI               | P value |
|----------------|-------------|--------------------|------------------------|----------|----------------------|---------|
| Low-risk       |             |                    |                        |          |                      |         |
| (1277) 95.2%   | 0           | 486 (34.9%)        | 3 (0.6%)               | 1        | /                    | /       |
|                | 1           | 568 (42.3%)        | 11 (1.9%)              |          |                      |         |
|                | 2           | 223 (16.6%)        | 11 (4.9%)              |          |                      |         |
| High-risk      |             |                    |                        |          |                      |         |
| (65) 4.8%      | 3           | 55 (4.1%)          | 6 (10.9%)              | 8.049    | 3.589–18.084         | 0.000   |
|                | 4           | 7 (0.5%)           | 1 (14.3%)              |          |                      |         |
|                | 5           | 3 (0.2%)           | 2 (66.7%)              |          |                      |         |

### Table 5: Hemorrhage condition between the experimental group and verification group with the comparison between actual and predicted incidence of hemorrhage

| Risk gradation | Score | CNEG (n, %) | IEG (n, %) | CNVG (n, %) | IVG (n, %) | P value |
|----------------|-------|-------------|------------|-------------|------------|---------|
| Low-risk       | 1277  | 95.2%       | 25 (2.0%)  | 434 (97.1%) | 9 (2.1%)   | 0.881   |
|                | 0     | 486 (34.9%) | 3 (0.6%)   | 142 (31.8%) | 1 (0.7%)   |         |
|                | 1     | 568 (42.3%) | 11 (1.9%)  | 201 (45.0%) | 3 (1.5%)   |         |
|                | 2     | 223 (16.6%) | 11 (4.9%)  | 91 (20.4%)  | 5 (5.5%)   |         |
| High-risk      | 65    | 4.8%        | 9 (13.8%)  | 13 (2.9%)   | 3 (23.1%)  | 0.400   |
|                | 3     | 55 (4.1%)   | 6 (10.9%)  | 11 (2.5%)   | 2 (18.2%)  |         |
|                | 4     | 7 (0.5%)    | 1 (14.3%)  | 2 (0.4%)    | 1 (50.0%)  |         |
|                | 5     | 3 (0.2%)    | 2 (66.7%)  | 0           | /          |         |

CNEG: Case number of experimental group; IEG: Incidence in experimental group.
CNVG: Case number of verification group; IVG: Incidence in verification group.
to the above factors, the research about how to rapidly and accurately predict the risk of PH and take appropriate perioperative interventions when multiple risk factors are present was limited. This study established a scoring system based on the relevant risk factors. It combined characteristics of LARG and compared them using a logistic regression rating system to achieve a better match (area under the receiver-operating characteristic (ROC) curve (AUC) was 0.748). It also further compared the difference between the prediction ratios and the actual bleeding ratios of the validation group; there was no statistical significance, indicating that the scoring system for PH risks has good prediction ability. When this scoring system is used in a clinical management, surgeons should observe the patient's perioperative general condition dynamically and, at the same time, dynamically grade the patient according to the risk factors of hemorrhage to predict PH. For example, if a patient’s preoperative assessment of the tumor is stage III, 1 point should be noted. If there is combined organ resection or more than 41 lymph nodes dissected, another point should be added. When the total score is ≥ 3, the patient should be categorized as high-risk, and the surgeon should closely monitor the patient's general condition. If digestive tract leakage occurs, 2 points are added and bleeding risk increases greatly. The surgeon should prepare for the possibility of hemorrhage and implement appropriate preventive measures, such as keeping the tube drainage unblocked, administering somatostatin to inhibit the secretion of digestive juices and so on. These measures promote the healing of leaks and reduce the risk of hemorrhage. Our study was based on large sample data from a single center, this scoring system can help young surgeons choose low bleeding risk patients to quickly and smoothly progress through the learning curve and promote the development and popularization of LARG.

There are some limitations of our study include the fact that the study is retrospective and non-randomized, and the sample size of patients with postoperative hemorrhage within 2 days (n = 18) and more than 1 week after surgery (n = 8) are small, thus there may be some selection bias if we evaluate separately according to the onset period of PH. In addition, the performance status for a few of patients was not recorded, which might result in some biases. So, this scoring system needs to be evaluated and validated by multicenter prospective trials.

In conclusion, this scoring system can effectively predict the risk of PH following LARG with D2 lymphadenectomy. It can also improve the risk awareness of PH after gastrectomy.

ACKNOWLEDGMENTS

The authors are thankful to Fujian Medical University Union Hospital for the management of our gastric cancer patient database.

CONFLICTS OF INTEREST

Drs. Xin-Sheng Xie, Jian-Xian Lin conceived the study, analyzed the data, and drafted the manuscript, Chang-Ming Huang, Chao-Hui Zheng helped critically revise the manuscript for important intellectual content. Ping Li, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Qi-Yue Chen, Long-Long Cao and Ru-Hong Tu helped collect data and design the study.

FUNDING

This study was funded by the National Key Clinical Specialty Discipline Construction program of China (No. [2012]649) and the Key Projects of Science and Technology Plan of Fujian Province (No. 2014Y0025) and Minimally invasive medical center of Fujian Province (2011708#). The youth research project of Fujian Province Health and Family Planning Commission (2014-1-48).

REFERENCES

1. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy—Japan Clinical Oncology Group study 9501. Journal of clinical oncology. 2004; 22:2767–2773.
2. Papenfuss WA, Kukar M, Oxenberg J, Attwood K, Nurkin S, Malhotra U, Wilkinson NW. Morbidity and mortality associated with gastrectomy for gastric cancer. Annals of surgical oncology. 2014; 21:3008–3014.
3. Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Annals of oncology. 2004; 15:1585–1595.
4. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric cancer. 2017; 20:1–19.
5. Hu JK, Wang K, Zhang B, Chen XZ, Chen ZY, Chen JP. D2 plus para-aortic lymphadenectomy versus standardized D2 lymphadenectomy in gastric cancer surgery. Surgery today. 2009; 39:207–213.
6. Yang J, Zhang JH, Huang YH, Chen B, Xu JB, Chen CQ, Cai SR, Zhan WH, He YL, Ma JP. Diagnosis and Treatment of Abdominal Arterial Bleeding After Radical Gastrectomy: a Retrospective Analysis of 1875 Consecutive Resections for Gastric Cancer. Journal of gastrointestinal surgery. 2016; 20:510–520.
7. Tanizawa Y, Bando E, Kawamura T, Tokunaga M, Ono H, Terashima M. Early postoperative anastomotic hemorrhage after gastrectomy for gastric cancer. Gastric cancer. 2010; 13:50–57.
8. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM,
Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017; 67:93–99.

9. International Union against Cancer (UICC) TNM Classification of Malignant Tumours. 7th edition. 2009. http://www.uicc.org/resources/tmn.

10. Wente MN, Veit JA, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, Yeo CJ, Buchler MW. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007; 142:20–25.

11. Yekebas EF, Wolfram L, Cataldeigirmen G, Habermann CR, Bogoevski D, Koenig AM, Kaifi J, Schurr PG, Bubenheim M, Nolte-Ernsting C, Adam G, Izbicki JR. Postpancreatectomy hemorrhage: diagnosis and treatment: an analysis in 1669 consecutive pancreatic resections. Annals of surgery. 2007; 246:269–280.

12. Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, Traverso LW, Yeo CJ, Buchler MW. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007; 142:761–768.

13. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66:7–30.

14. Lee JH, Han HS, Lee JH. A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: early results. Surg Endosc. 2005; 19:168–173.

15. Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, Ryu SW, Lee HJ, Song KY. Morbidity and Mortality of Laparoscopic Gastrectomy Versus Open Gastrectomy for Gastric Cancer. Annals of Surgery. 2010; 251:417–420.

16. Yasunaga H, Horiguchi H, Kuwabara K, Matsuda S, Fushimi K, Hashimoto H, Ayanian JZ. Outcomes After Laparoscopic or Open Distal Gastrectomy for Early-Stage Gastric Cancer. Annals of Surgery. 2013; 257:640–646.

17. Huscher CGS, Mingoli A, Sgarzini G, Sansonetti A, Di Paola M, Recher A, Ponzano C. Laparoscopic Versus Open Subtotal Gastrectomy for Distal Gastric Cancer. Annals of Surgery. 2005; 241:232–237.

18. Fujiwara M, Kodera Y, Misawa K, Kinoshita M, Kinoshita T, Miura S, Ohashi N, Nakayama G, Koike M, Nakao A. Longterm Outcomes of Early-Stage Gastric Carcinoma Patients Treated with Laparoscopy-Assisted Surgery. Journal of the American College of Surgeons. 2008; 206:138–143.

19. Tokioka S, Umegaki E, Murano M, Takeuchi N, Takeuchi T, Kawakami K, Yoda Y, Kojima Y, Higuchi K. Utility and problems of endoscopic submucosal dissection for early gastric cancer in elderly patients. J Gastroenterol Hepatol. 2012; 27:63–69.

20. Mita K, Ito H, Murabayashi R, Sueyoshi K, Asakawa H, Nabetani M, Kamasako A, Koizumi K, Hayashi T. Postoperative bleeding complications after gastric cancer surgery in patients receiving anticoagulation and/or antiplatelet agents. Annals of surgical oncology. 2012; 19:3745–3752.

21. Song W, Yuan Y, Peng J, Chen J, Han F, Cai S, Zhan W, He Y. The delayed massive hemorrhage after gastrectomy in patients with gastric cancer: characteristics, management opinions and risk factors. European journal of surgical oncology. 2014; 40:1299–1306.

22. Park JY, Kim YW, Eom BW, Yoon HM, Lee JH, Ryu KW, Cho SJ, Lee JY, Kim CG, Choi DJ. Unique patterns and proper management of postgastrectomy bleeding in patients with gastric cancer. Surgery. 2014; 155:1023–1029.

23. Jeong O, Park YK, Ryu SY, Kim DY, Kim HK, Jeong MR. Predisposing factors and management of postoperative bleeding after radical gastrectomy for gastric carcinoma. Surg Today. 2011; 41:363–368.